Your session is about to expire
← Back to Search
Enfortumab vedotin for Bladder Cancer (EV-201 Trial)
EV-201 Trial Summary
This trial will test the experimental drug enfortumab vedotin on patients with urothelial cancer who have been previously treated with an immune checkpoint inhibitor. The study will look at if the cancer shrinks with treatment and also the side effects of the drug.
- Bladder Cancer
- Urologic Cancers
- Transitional Cell Carcinoma
- Ureteral Tumors
- Urethral Tumors
- Kidney Tumors
EV-201 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEV-201 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 219 Patients • NCT03219333EV-201 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have active cancer that has spread to your brain or spinal cord.You have experienced heart, digestive system, eye, or lung problems related to immunotherapy.You have participated in a study using enfortumab vedotin or have been treated with other medicines similar to enfortumab vedotin.Your cancer has spread to other parts of your body or is in an advanced stage that cannot be surgically removed.You have severe pain from your tumor that is not well controlled or you have a risk of your spinal cord being compressed by the tumor.
- Group 1: Enfortumab vedotin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have opted to take part in this experiment?
"At present, no further participants are being sought for this medical trial. Initially posted on October 8th 2017 and last updated June 13th 2022, the study is now closed to new patients. If one desires to explore alternative trials in urologic neoplasms there are 2,825 studies available while 18 clinical trials have opened their doors for Enfortumab vedotin enrolment."
Is Enfortumab vedotin a safe and reliable treatment option for patients?
"Based on our internal assessment, enfortumab vedotin was given a rating of 2 because this is currently at the Phase 2 stage and there are limited efficacy data available."
Is this experimental research novel in terms of its approach?
"Seagen Inc. initiated the inaugural trial for Enfortumab vedotin in 2014, featuring a cohort of 213 participants. This Phase 1 clinical trial was successful enough to gain approval and since then 18 separate medical studies have been launched in 377 cities from 44 nations."
How many healthcare facilities are providing this clinical exploration within the state?
"This clinical trial is currently operational at 69 distinct sites, including Davis, Scottsdale and Tualatin. For the sake of convenience, it is best to enlist in a location near you so that travel demands are kept minimal."
To what type of ailments is enfortumab vedotin commonly prescribed?
"Enfortumab vedotin can be utilized for therapeutic procedures, attacking metastatic urothelial cancer and aiding in pharmacotherapy."
Has Enfortumab vedotin been evaluated in any other research initiatives?
"In 2014, US00019 was the first site to research enfortumab vedotin. Currently, two studies have already been completed while 18 are in progress with a significant number of those trials being conducted from Davis, Arizona."
Is recruitment for this trial still open?
"According to the data on clinicaltrials.gov, this medical study has ceased its search for participants as of June 13th 2022. Despite that, there are still 2843 other trials in need of volunteers at present time."
Share this study with friends
Copy Link
Messenger